Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase 3 (MAPK3/ERK1) and mitogen-activated protein kinase 1 (MAPK1/ERK2) are highly homologous serine/threonine-protein kinases that function as the terminal effectors of the canonical RAS-RAF-MEK-ERK signaling cascade. Upon activation by upstream dual-specificity MEK1/2 kinases, ERK1/2 phosphorylate a vast array of cytoplasmic and nuclear substrates, including transcription factors like Elk-1 and c-Fos, thereby regulating critical cellular processes such as proliferation, differentiation, survival, and cell cycle progression. Dysregulation and hyperactivation of the MAPK3/MAPK1 pathway are implicated in approximately 40% of human cancers, particularly those driven by oncogenic mutations in upstream regulators like KRAS, NRAS, and BRAF.\n\nConsequently, MAPK3/MAPK1 represents a highly attractive therapeutic target in oncology, especially for overcoming acquired resistance to upstream RAF and MEK inhibitors. Several small-molecule ERK1/2 inhibitors, such as ulixertinib, temuterkib, and GDC-0994, are currently undergoing clinical evaluation. However, targeting these kinases presents significant therapeutic challenges, including dose-limiting toxicities such as severe dermatologic rashes, gastrointestinal issues, and retinopathy, as well as the rapid emergence of drug resistance through compensatory bypass pathways like the PI3K/AKT/mTOR axis.
ERK1/2 inhibitor
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase 3/Mitogen-activated protein kinase 1 (MAPK3/MAPK1).